Investigating the Protective Effects of a Citrus Flavonoid on the Retardation Morphogenesis of the Oligodendroglia-like Cell Line by Rnd2 Knockdown.

RNA cell line clustered regularly interspaced short palindromic repeats disease flavonoid monomeric GTP-binding proteins morphogenesis oligodendroglia phosphotransferases signal transduction small interfering

Journal

Neurology international
ISSN: 2035-8385
Titre abrégé: Neurol Int
Pays: Switzerland
ID NLM: 101551564

Informations de publication

Date de publication:
26 Dec 2023
Historique:
received: 26 07 2023
revised: 19 12 2023
accepted: 22 12 2023
medline: 22 1 2024
pubmed: 22 1 2024
entrez: 22 1 2024
Statut: epublish

Résumé

Recent discoveries suggest links between abnormalities in cell morphogenesis in the brain and the functional deficiency of molecules controlling signal transduction in glial cells such as oligodendroglia. Rnd2 is one such molecule and one of the Rho family monomeric GTP-binding proteins. Despite the currently known functions of Rnd2, its precise roles as it relates to cell morphogenesis and disease state remain to be elucidated. First, we showed that signaling through the loss of function of the

Identifiants

pubmed: 38251051
pii: neurolint16010003
doi: 10.3390/neurolint16010003
doi:

Types de publication

Journal Article

Langues

eng

Pagination

33-61

Déclaration de conflit d'intérêts

Author Yu Oka, Maki Ishibashi and Yuki Ishida was employed by the Personal Health Care Division, Hayashibara Co., Ltd., Okayama-shi, Okayama 702-8006, Japan. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Auteurs

Shoya Fukatsu (S)

Laboratory of Molecular Neurology, Tokyo University of Pharmacy and Life Sciences, Tokyo 192-0392, Japan.

Yuki Miyamoto (Y)

Laboratory of Molecular Neurology, Tokyo University of Pharmacy and Life Sciences, Tokyo 192-0392, Japan.
Laboratory of Molecular Pharmacology, National Research Institute for Child Health and Development, Setagaya-ku, Tokyo 157-8535, Japan.

Yu Oka (Y)

Personal Health Care Division, Hayashibara Co., Ltd., Okayama 702-8006, Japan.

Maki Ishibashi (M)

Personal Health Care Division, Hayashibara Co., Ltd., Okayama 702-8006, Japan.

Remina Shirai (R)

Laboratory of Molecular Neurology, Tokyo University of Pharmacy and Life Sciences, Tokyo 192-0392, Japan.

Yuki Ishida (Y)

Personal Health Care Division, Hayashibara Co., Ltd., Okayama 702-8006, Japan.

Shin Endo (S)

Personal Health Care Division, Hayashibara Co., Ltd., Okayama 702-8006, Japan.

Hironori Katoh (H)

Department of Biological Chemistry, Graduate School of Science, Osaka Metropolitan University, Osaka 599-8531, Japan.

Junji Yamauchi (J)

Laboratory of Molecular Neurology, Tokyo University of Pharmacy and Life Sciences, Tokyo 192-0392, Japan.
Laboratory of Molecular Pharmacology, National Research Institute for Child Health and Development, Setagaya-ku, Tokyo 157-8535, Japan.
Diabetic Neuropathy Project, Tokyo Metropolitan Institute of Medical Science, Setagaya-ku, Tokyo 156-8506, Japan.

Classifications MeSH